What GHRP-6 is
Growth hormone-releasing peptide-6 (GHRP-6) is a synthetic hexapeptide that activates the ghrelin receptor and can provoke pituitary growth-hormone release. It is not recombinant growth hormone and has no FDA-approved U.S. drug product, indication, or dose.
GHRP-6, GHRP-2, ipamorelin, ibutamoren, macimorelin, and natural ghrelin can share receptor biology while remaining different molecules with different evidence and regulatory status. Findings or approvals for one cannot be assigned to another.
Human evidence is mostly short endocrine testing
Small studies show that intravenous GHRP-6 can provoke growth-hormone release. In 20 patients assessed against an insulin-tolerance test, GHRP-6 alone or with GHRH separated study-defined deficient and sufficient groups under the investigators’ conditions.[1] Four repeat tests in 17 healthy adults found the combined GHRH plus GHRP-6 hormone response reproducible.[2]
These are diagnostic physiology findings, not trials of muscle growth, fat loss, recovery, injury healing, longevity, or athletic performance. No reliable clinical-outcome evidence establishes GHRP-6 for those uses.
Metabolic and appetite effects complicate the story
Ghrelin-receptor signaling connects growth-hormone release with appetite and metabolism. A ten-person mechanistic study found acute GHRP-6-associated increases in glucose and insulin under growth-hormone receptor blockade in the non-fasting state, consistent with tissue-specific insulin-resistance effects in that experimental setting.[3]
That narrow experiment cannot predict ordinary long-term use, but it shows why describing GHRP-6 as a clean or metabolically neutral GH booster is not justified.
FDA identifies unresolved safety risks
FDA places GHRP-6 in category 2 of its 503B interim compounding policy. It cites possible immunogenicity from aggregation and peptide-related impurities, very limited safety information, potential cortisol effects, and increased blood glucose associated with reduced insulin sensitivity.[4]
There is no approved adverse-reaction table or long-term safety program for routine GHRP-6 use. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[5]
Regulatory and sport status
GHRP-6 is unapproved in the United States and prohibited in sport as a growth-hormone-releasing factor under the current World Anti-Doping Agency list.[6] Teloryx does not publish a GHRP-6 dose, cycle, stack, or reconstitution recipe.